The federal government should drive drug development — not leave it to Big Pharma to put profits over public health
The Trump Administration's policies have worsened the US healthcare crisis, with rising drug prices and cuts to essential programs like Medicaid. A proposed institute at the National Institutes of Health could develop new medications in the public interest and distribute them at not-for-profit rates.
The US healthcare system is in crisis, with millions of Americans suffering due to high drug prices and lack of access to healthcare. Under the Trump Administration, healthcare costs have soared, with drug prices outpacing inflation. The administration has cut over $1 trillion from essential programs like Medicaid. In contrast, countries like Canada have more affordable healthcare systems, with prices for prescription drugs significantly lower. A proposed solution is to create a new institute at the National Institutes of Health to develop new medications in the public interest. The Medicines for the People Act aims to achieve this, developing high-quality medications and distributing them at not-for-profit rates.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.